News UK watchdog takes first action on oral weight drug adverts Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.
News Novo faces delay in US review of haemophilia drug The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.
News New diabetes and obesity studies making waves at EASD As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
News Two men charged with infiltrating fake Ozempic into US Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to distributors in the US.
News Novo turns to Hengrui for another oral obesity drug Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
News Lilly's rival to Novo's new Awiqli insulin gets FDA approval The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.